GCC REACH Cohort 4

Cellular immunotherapy (CI), including CAR T-cell therapy, has revolutionized cancer treatment for patients with relapsed or refractory hematologic malignancies. Yet, its broader adoption is limited by life-threatening toxicities—specifically cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Our solution is a first-in-class, non-invasive diagnostic platform that analyzes exhaled breath volatile organic compounds (VOCs) to predict these toxicities before therapy is administered. This enables real-time, bedside-compatible risk stratification and timely intervention—reducing ICU admissions and supporting the safe expansion of CI into outpatient and community oncology settings.